No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
US OptionsDetailed Quotes
NVAX250110C17000
- 0.07
- +0.05+250.00%
15min DelayClose Jan 7 16:00 ET
0.07High0.07Low
0.07Open0.02Pre Close2 Volume3 Open Interest17.00Strike Price14.00Turnover615.27%IV57.76%PremiumJan 10, 2025Expiry Date0.00Intrinsic Value100Multiplier3DDays to Expiry0.07Extrinsic Value100Contract SizeAmericanOptions Type0.2935Delta0.0577Gamma12.73Leverage Ratio-0.3608Theta0.0002Rho3.74Eff Leverage0.0033Vega
Intraday
- 5D
- Daily
News
Options Alert: Why Novavax (NVAX) Could Be the Biotech Hero of Trump 2.0
US Records First Human Bird Flu Death, High Levels Of Respiratory Illnesses: Vaccine Stocks Rally
Moderna, Novavax and Other Vaccine Names Extend Gains Amid COVID/flu Concerns
Moderna Stock Jumps Amid Bird Flu Vaccine Hope After First U.S. Death -- Barrons.com
Why Novavax (NVAX) Stock Is Rising
Shares of Vaccine Makers Are Trading Higher After the First Bird Flu Death Was Reporting in the US. Additionally, a Recent DCD Report Noted an Increase in Acute Respiratory Illness Activity.